Stereotaxis has secured up to $24 million in convertible note financing from accredited investors, including entities tied to certain company directors, the surgical robotics firm disclosed alongside its Q3 2026 earnings. The initial closing delivered $12 million in gross proceeds on November 9, with a further $12 million available at the company's discretion once it hits certain regulatory milestones, according to the company's SEC filing. The notes carry 10% annual interest, mature in three years, and convert into common stock at a 30% premium to the recent volume-weighted price.
The financing lands as Stereotaxis reported Q3 revenue of $8.9 million, up 20% year-over-year from $7.5 million, with system revenue climbing 60% to $3.0 million and recurring revenue up 6% to $5.9 million. Pro forma cash, including the note draw, reaches roughly $28 million.
A small check that matters for a company running close to the edge
Stereotaxis makes the GenesisX and Genesis robotic magnetic-navigation systems, plus the Synchrony digital operating room platform, used to steer catheters remotely during complex cardiac ablation procedures. The company held just $4.0 million in cash before this raise, a thin cushion for a medical device maker still working toward sustained profitability.
CEO David Fischel framed the company's strategy as shifting away from expensive capital equipment sales toward a broader, more accessible and scalable systems portfolio alongside disposable catheter products — a recurring-revenue model that medtech investors tend to reward with steadier margins than one-off capital sales. The note's structure, tying a second tranche to regulatory milestones rather than handing over the full $24 million at once, reflects a cautious bet by investors that near-term FDA or regulatory wins are plausible but not guaranteed.
Surgical robotics' crowded, expensive middle tier
Stereotaxis occupies a narrow niche adjacent to giants like Intuitive Surgical, but focused specifically on magnetic catheter navigation for cardiac procedures rather than general-purpose surgical arms. Its recent moves — completing the acquisition of catheter-robotics firm Robocath and announcing a collaboration with Canon — point toward building a broader portfolio rather than competing head-on with larger surgical robot platforms.
That strategy carries real execution risk: smaller surgical robotics companies have struggled to fund growth between bigger financing rounds, and a 10%-interest convertible note is a relatively expensive way to bridge that gap compared to an equity raise at a higher valuation. The 60% jump in system revenue suggests hospitals are buying new units, not just service contracts, which is the trend Stereotaxis needs to sustain if it wants its next raise to come on better terms. Whether the second $12 million tranche gets triggered will be the clearest signal of how close the company's regulatory pipeline actually is to payoff.